Рекомендации 2016 Европейского общества кардиологов по диагностике и лечению острой и хронической сердечной недостаточности (избранные положения)

van Riet E.E.S. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion / E.E.S. van Riet, A.W. Hoes, A. Limburg et al. // Eur. J. Heart Fail. –2014. – Vol. 16. – P. 772–777.

Kelder J.C. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure / J.C. Kelder, M.J. Cramer, J. van Wijngaarden et al. // Circulation. – 2011. – Vol. 124. – P. 2865–2873.

Boonman-de Winter L.J.M. Efficiently screening heart failure in patients with type 2 diabetes / L.J.M. Boonman-de Winter, F.H. Rutten, M.J. Cramer et al. // Eur. J. Heart Fail. – 2015. – Vol. 17. – P. 187–195.

Rutten F.H. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study / F.H. Rutten, K.G.M. Moons, M.-J.M. Cramer et al. // BMJ. – 2005. – Vol. 331. – P. 1379.

Hawkins N.M. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology / N.M. Hawkins, M.C. Petrie, P.S. Jhund et al. // Eur. J. Heart Fail. – 2009. – Vol. 11. – P. 130–139.

Daniels L.B. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study / L.B. Daniels, P. Clopton, V. Bhalla et al. // Am. Heart J. – 2006. – Vol. 151. – P. 999–1005.

Thibodeau J.T. Characterization of a novel symptom of advanced heart failure: bendopnea / Thibodeau J.T., Turer A.T., Gualano S.K. et al. // JACC Heart Fail. – 2014. – Vol. 2. – P. 24–31.

Stewart S. The current cost of heart failure to the National Health Service in the UK / S. Stewart, A. Jenkins, S. Buchan et al. // Eur. J. Heart Fail. – 2002. – Vol. 4 – P. 361–371.

Gheorghiade M. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics’, clinicians’, industry’s, regulators’, and payers’ perspectives / M. Gheorghiade, A.N. Shah, M. Vaduganathan et al. // Heart Fail. Clin. – 2013. – Vol. 9. – P. 285–290, v–vi.

Ambrosy A.P. The global health and economic burden of hospitalizations for heart failure / A.P. Ambrosy, G.C. Fonarow, J. Butler et al. // J. Am. Coll. Cardiol. – 2014. – Vol. 63. – P. 1123–1133.

McMurray J.J. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure / McMurray J.J., Packer M., Desai A.S. et al. // N. Engl. J. Med. – 2014. – Vol. 371. – P. 993–1004.

Pitt B. The effect of spironolactone on morbidity and mortality in patients with severe heart failure / B. Pitt, F. Zannad, W.J. Remme et al. // N. Engl. J. Med. – 1999. – Vol. 341. – P. 709–717.

Zannad F. Eplerenone in patients with systolic heart failure and mild symptoms / F. Zannad, J.J.V. McMurray, H. Krum et al. // N. Engl. J. Med. – 2011. – Vol. 364. – P. 11–21.